Zimhi - A Higher-Dose Injectable Naloxone for Opioid Overdose

Date: April 18, 2022 Issue #:  1648Summary:  The FDA has approved a higher-dose injectable formulation of the opioid antagonist naloxone (Zimhi– Adamis) for emergency treatment of opioid overdose. A single IM or SC injection of the new formulation delivers 5 mg of naloxone; injectable formulations that deliver 0.4 mg or 2 mg of the drug have been available for years. Naloxone is also available in intranasal formulations for the same indi cation (see Table 1).
Source: The Medical Letter - Category: Drugs & Pharmacology Authors: Tags: Drug abuse Kloxxado Naloxone Narcan opioid abuse Opioid dependence Opioids Zimhi Source Type: research